Literature DB >> 1699954

Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells.

G J Ciambrone1, P J McKeown-Longo.   

Abstract

Polyclonal antibodies against plasminogen activator inhibitor type-I (PAI-1) caused rapid retraction and rounding of substrate-attached HT-1080 cells. The kinetics and extent of antibody-mediated cell rounding were not dependent on either urokinase or plasmin activity. Cells adherent to vitronectin-coated substrates detached within 2 h of antibody addition. Cells adherent to fibronectin were unaffected by the antibodies. Immunoblotting of substrate-attached material indicated that HT-1080 cells deposited PAI-1 into vitronectin, but not fibronectin, dependent contacts. These data suggest that the antibody-mediated cell rounding resulted from a steric disruption of vitronectin-dependent adhesions, indicating that the binding site on vitronectin for PAI-1 is near, but does not overlap, the binding site for vitronectin receptor. The accumulation of PAI-1 into vitronectin-dependent adhesion sites correlated temporally with the preferential degradation of fibronectin from the substrate. HT-1080 cells adherent to either fibronectin or vitronectin were able to activate exogenous plasminogen to plasmin. Plasmin levels were increased 200% on cells adherent to fibronectin and 100% on cells adherent to vitronectin. In the presence of a neutralizing antibody against PAI-1, vitronectin adherent cells activated plasminogen to the same extent as fibronectin adherent cells. Plasmin levels of 200% above baseline were associated with retraction of cells from the substrate. The ability of vitronectin adherent cells to activate exogenous plasmin was completely blocked in the presence of neutralizing antibodies against urokinase. These data represent the first demonstration that vitronectin-associated PAI-1 regulates urokinase in focal contact areas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699954      PMCID: PMC2116338          DOI: 10.1083/jcb.111.5.2183

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  35 in total

1.  Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin.

Authors:  E M Salonen; A Vaheri; J Pöllänen; R Stephens; P Andreasen; M Mayer; K Danø; J Gailit; E Ruoslahti
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

2.  Characterization of a newly derived human sarcoma cell line (HT-1080).

Authors:  S Rasheed; W A Nelson-Rees; E M Toth; P Arnstein; M B Gardner
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

3.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

4.  Morphology and cellular origins of substrate-attached material from mouse fibroblasts.

Authors:  J J Rosen; L A Culp
Journal:  Exp Cell Res       Date:  1977-06       Impact factor: 3.905

5.  Regulation of fibronectin biosynthesis by glucocorticoids in human fibrosarcoma cells and normal fibroblasts.

Authors:  N Oliver; R F Newby; L T Furcht; S Bourgeois
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

6.  Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.

Authors:  J Pöllänen; O Saksela; E M Salonen; P Andreasen; L Nielsen; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1987-04       Impact factor: 10.539

7.  Cell attachment on replicas of SDS polyacrylamide gels reveals two adhesive plasma proteins.

Authors:  E G Hayman; E Engvall; E A'Hearn; D Barnes; M Pierschbacher; E Ruoslahti
Journal:  J Cell Biol       Date:  1982-10       Impact factor: 10.539

8.  Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression.

Authors:  Z Werb; P M Tremble; O Behrendtsen; E Crowley; C H Damsky
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

9.  Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.

Authors:  R W Stephens; J Pöllänen; H Tapiovaara; K C Leung; P S Sim; E M Salonen; E Rønne; N Behrendt; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1989-05       Impact factor: 10.539

10.  Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.

Authors:  J Pöllänen; K Hedman; L S Nielsen; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1988-01       Impact factor: 10.539

View more
  11 in total

1.  Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines.

Authors:  D R Senger
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

2.  Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines.

Authors:  A Angelucci; S D'Ascenzo; C Festuccia; G L Gravina; M Bologna; V Dolo; A Pavan
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 3.  The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis.

Authors:  J Nip; P Brodt
Journal:  Cancer Metastasis Rev       Date:  1995-09       Impact factor: 9.264

4.  Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC).

Authors:  S Rosenblatt; J A Bassuk; C E Alpers; E H Sage; R Timpl; K T Preissner
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

5.  P52PAI-1 gene expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells: mechanism of induction and involvement in the morphological response.

Authors:  P J Higgins; M P Ryan; D M Jelley
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

6.  A dual role for caveolin-1 in the regulation of fibronectin matrix assembly by uPAR.

Authors:  Elizabeth Monaghan-Benson; Cynthia Corley Mastick; Paula J McKeown-Longo
Journal:  J Cell Sci       Date:  2008-10-28       Impact factor: 5.285

7.  The urokinase receptor is required for human monocyte chemotaxis in vitro.

Authors:  M R Gyetko; R F Todd; C C Wilkinson; R G Sitrin
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

8.  Cell-shape-dependent modulation of p52(PAI-1) gene expression involves a secondary response pathway.

Authors:  P J Higgins; L Staiano-Coico; M P Ryan
Journal:  Biochem J       Date:  1995-03-01       Impact factor: 3.857

Review 9.  Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.

Authors:  S Mohanam; R E Sawaya; M Yamamoto; J M Bruner; G L Nicholson; J S Rao
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.

Authors:  H J Ehrlich; R K Gebbink; K T Preissner; J Keijer; N L Esmon; K Mertens; H Pannekoek
Journal:  J Cell Biol       Date:  1991-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.